Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): Rationale and design

European Journal of Heart Failure

Volumn 14, Issue 8, 2012, Pages 946-953

  Ghio, Stefano ^a,j   Bonderman, Diana ^b,j   Felix, Stephan B ^c,j   Ghofrani, Hossein A ^d,j   Michelakis, Evangelos D ^e,j   Mitrovic, Veselin ^f,j   Oudiz, Ronald J ^g,j   Frey, Reiner ^h   Roessig, Lothar ^h,j   Semigran, Marc J ^a,i,j  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

^e UNIVERSITY OF ALBERTA   (Canada)

^f KERCKHOFF HEART CENTER   (Germany)

^g HARBOR UCLA MEDICAL CENTER   (United States)

^h BAYER PHARMA AG   (Germany)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j LEPHT ^*  (United States)

more..

Author keywords

Clinical trial; Pulmonary hypertension; Riociguat; Soluble guanylate cyclase stimulator; Systolic heart failure

Indexed keywords

RIOCIGUAT;

ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; EXERCISE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LONG TERM CARE; LUNG ARTERY PRESSURE; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; GUANYLATE CYCLASE; HEART FAILURE, SYSTOLIC; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; PYRAZOLES; PYRIMIDINES; QUALITY OF LIFE; RESEARCH DESIGN; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84864452791     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs071     Document Type: Article

References (35)

1. Hoeper MM, Barberà JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, Redfield MM, Robbins IM, Souza R, Torbicki A, McGoon M. Diagnosis, assessment, and treatment of nonpulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S85-S96.
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl.):S43-S54.
3. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001;37:183-188.
4. Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol 2010;7:648-659.
5. Haddad F, Kudelko K, Mercier O, Vrtovec B, Zamanian RT, de Jesus Perez V. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis 2011;54:154-167.
6. Khush KK, Tasissa G, Butler J, McGlothlin D, De Marco T. Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. Am Heart J 2009;157:1026-1034.
7. Butler J, Chomsky DB, Wilson Jr. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 1999;34:1802-1806.
8. Cappola TP, Felker GM, Kao WH, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002;105:1663-1668.
9. Grigioni F, Potena L, Galie N, Fallani F, Bigliardi M, Coccolo F, Magnani G, Manes A, Barbieri A, Fucili A, Magelli C, Branzi A. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant 2006;25:1241-1246.
10. Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Kober L, Torp-Pedersen C, Hassager C. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007;99:1146-1150.
11. Chatterjee NA, Lewis GD. What is the prognostic significance of pulmonary hypertension in heart failure? Circ Heart Fail 2011;4:541-545.
12. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, KlepetkoW, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Sechtem U, Al Attar N, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Domenech MT, Vonk-Noordegraaf A, Zamorano JL. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537.
13. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2010;123:2263-2273.
14. Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J, Ewert R, Weimann G, Grimminger F. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792-799.
15. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bölkow D, Weissmann N, Muck W, Unger S, Wensing G, Schermuly RT, Ghofrani HA. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33:785-792.
16. Mitrovic V, Swidnicki B, Ghofrani A, Mück W, Kirschbaum N, Mittendorf J, Stasch JP, Wensing G, Frey R, Lentini S. Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator in patients with biventricular heart failure. BMC Pharmacol 2009;9(Suppl 1):P51
17. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the european society of intensive care medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
18. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
19. Yokota T, Tsutsui H. New aspects of guidelines for treatment of chronic heart failure (JCS 2010). Nihon Rinsho 2011;69:1691-1697.
20. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
21. Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, Cortina A, Cserhalmi L, Follath F, Jensen G, Kayanakis J, Lie KI, Mancia G, Skene AM. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997;349: 971-977.
22. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-1475.
23. Guazzi M, Myers J, Peberdy MA, Bensimhon D, Chase P, Arena R. Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil. Int J Cardiol 2010;144: 410-412.
24. Katz SD, Biasucci L, Sabba C, Strom JA, Jondeau G, Galvao M, Solomon S, Nikolic SD, Forman R, LeJemtel TH. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 1992;19:918-925.
25. Mathier MA, Rose GA, Fifer MA, Miyamoto MI, Dinsmore RE, Castano HH, Dec GW, Palacios IF, Semigran MJ. Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1998;32: 216-224.
26. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000;102:1718-1723.
27. Meyer B, Mortl D, Strecker K, Hulsmann M, Kulemann V, Neunteufl T, Pacher R, Berger R. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol 2005; 46:1011-1018.
28. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr., Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN. Combination of isosorbide dinitrate hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057.
29. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005;97:618-628.
30. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212-215.
31. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC Jr. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 2003;107:686-689.
32. Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann LS,Wellkisch K, Geschka S, Relle K, Hocher B, Stasch JP. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens 2010;28:1666-1675.
33. Lewis GD, Murphy RM, Shah RV, Pappagianopoulos PP, Malhotra R, Bloch KD, Systrom DM, Semigran MJ. Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. Circ Heart Fail 2011;4:276-285.
34. Stevenson LW, Zile M, Bennett TD, Kueffer FJ, Jessup ML, Adamson P, Abraham WT, Manda V, Bourge RC. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail 2010;3:580-587.
35. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011;377:658-666.